PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While PDL BioPharma hopes to advance its lead product Nuvion into a pivotal ulcerative colitis trial by mid-2007, the firm is also looking to expand its acute care portfolio through several anticipated partnerships and the acquisition of a commercial product.